Study guide

13.3 Hyperbilirubinemia

CCRN Neonatal Critical Care Certification Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction and Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Retakes, and Renewal 1.3 Synergy Model, Blueprint Weights, and NICU Foundations

2 Cardiovascular: Transition and Congenital Disease

2.1 Fetal Circulation, PDA, PFO, and Transitional Physiology 2.2 Congenital Heart Defects 2.3 Neonatal Cardiac Surgery and Postoperative Care

3 Cardiovascular: Instability and Rhythm

3.1 Hemodynamic Instability, Monitoring, and Vascular Access 3.2 Heart Failure, Tamponade, and Acquired Cardiac Conditions 3.3 Neonatal Dysrhythmias and Cardioversion

4 Respiratory: Transition, RDS, Failure, and Apnea

4.1 RDS, Surfactant, TTN, and Transitional Respiratory Failure 4.2 Acute Respiratory Distress, Failure, and Assisted Ventilation 4.3 Apnea of Prematurity

5 Respiratory: Aspiration, Chronic Lung Disease, Anomalies, and PPHN

5.1 Aspiration and Meconium Aspiration Syndrome 5.2 Chronic Lung Disease, BPD, and Pulmonary Interstitial Emphysema 5.3 Congenital Respiratory Anomalies and Surgery 5.4 PPHN, Pulmonary Hemorrhage, Pleural Disease, and Infection

6 Endocrine Disorders

6.1 Neonatal Glucose Homeostasis 6.2 Calcium, Thyroid, and Adrenal Disorders 6.3 Metabolism Disorders and Inborn Errors

7 Hematology and Immunology

7.1 Anemia, Polycythemia, Sickle Cell, and Leukopenia 7.2 Coagulopathies, DIC, Thrombocytopenia, and Factor Deficiencies 7.3 Hemolytic Disease of the Newborn

8 Gastrointestinal Disorders

8.1 Congenital and Acquired GI Abnormalities 8.2 Necrotizing Enterocolitis 8.3 Nutrition, Feeding Intolerance, Malabsorption, GER, and Lactation 8.4 Hepatic Failure, Biliary Atresia, and Cholestasis

9 Renal, Genitourinary, and Integumentary Care

9.1 Congenital and Acquired Renal and GU Conditions 9.2 Gestational-Age Skin, TEWL, Humidity, and Congenital Skin Conditions 9.3 Infiltration, Wounds, Diaper Dermatitis, and Skin Infection

10 Musculoskeletal Conditions and Congenital Neurology

10.1 Acquired and Congenital Musculoskeletal Conditions 10.2 Congenital Neurologic Abnormalities and Surgery 10.3 Neonatal Seizures and CNS Infection

11 Neurologic Injury, Neuroprotection, and Infant State

11.1 IVH and Extra/Intracranial Hemorrhage 11.2 HIE, PVL, Stroke, and Therapeutic Hypothermia 11.3 Pain, Sedation, and State Dysregulation

12 Behavioral and Psychosocial Care in the NICU

12.1 Family Systems, Engagement, and Caregiver Confidence 12.2 Families in Crisis, Grief, and Escalation 12.3 Culture, Communication, Language, Abuse, and Neglect

13 Multisystem: Homeostasis

13.1 Acid-Base and Fluid/Electrolyte Imbalance 13.2 Thermoregulation 13.3 Hyperbilirubinemia 13.4 Infant of a Diabetic Mother

14 Multisystem: Sepsis, Shock, and Hospital-Acquired Harm

14.1 Early- and Late-Onset Sepsis 14.2 Shock States 14.3 Healthcare-Acquired Conditions and Multi-Organ Failure

15 Multisystem: Perinatal Injury and Genetic Conditions

15.1 Birth Trauma and Hydrops Fetalis 15.2 Life-Threatening Maternal/Fetal Complications 15.3 Genetic Conditions, Syndromes, and Trisomies 15.4 Sequences: VACTERL and Pierre Robin

16 Multisystem: Advanced Support and Continuum of Care

16.1 ECMO, CRRT, Dialysis, and Other Advanced Therapies 16.2 Growth, Developmental Delay, and Sensory Impairment 16.3 Toxin and Drug Exposure, NAS, and FASD 16.4 Terminal Conditions, Palliative Care, and End of Life

17 Professional Caring: Advocacy through Collaboration

17.1 Advocacy and Moral Agency 17.2 Caring Practices 17.3 Clinical Inquiry 17.4 Collaboration

18 Professional Caring: Learning, Diversity, and Systems Thinking

18.1 Facilitation of Learning 18.2 Response to Diversity 18.3 Systems Thinking

13.3 Hyperbilirubinemia

Key Takeaways Explain This Topic AI

Unconjugated bilirubin from heme breakdown is albumin-bound, conjugated in the liver, and excreted in bile; delayed stooling and hemolysis raise the load.

Screen with transcutaneous bilirubin (TcB); confirm and treat with total serum bilirubin (TSB). After phototherapy starts, use TSB, not TcB.

AAP 2022 uses hour-specific, gestation-based phototherapy and exchange graphs with neurotoxicity risk factors; AACN does not publish those graphs as an official CCRN nomogram.

A positive DAT supports isoimmune hemolysis; conjugated hyperbilirubinemia is cholestasis until proven otherwise and is not a kernicterus-phototherapy problem.

Intensive phototherapy means high-irradiance blue light and maximal skin exposure with eye protection; fiberoptic blankets are usually adjuncts; feed milk, not extra water.

Last updated: September 2026

13.3 Hyperbilirubinemia

Quick Answer: Newborns have a high red-cell turnover, immature UDP-glucuronosyltransferase (UGT1A1) , and enterohepatic recirculation, so unconjugated bilirubin rises. Screen with TcB ; treat and follow with TSB . AAP 2022 phototherapy and exchange decisions are hour-specific and gestation-specific , with lower thresholds when neurotoxicity risk factors are present. AACN Certification Corporation does not publish those graphs as an official CCRN nomogram—use the current AAP figures and your unit protocol, and do not invent a fake milligram-per-deciliter table as “the AACN numbers.” A positive DAT supports isoimmune hemolysis (chapter 7). Conjugated hyperbilirubinemia is cholestasis, not physiologic jaundice. Kernicterus is permanent bilirubin injury to basal ganglia and brainstem nuclei. Intensive phototherapy is high-irradiance blue light and exposed skin with eye shields ; fiberoptic devices are usually lower-irradiance adjuncts. Hydrate with milk , not extra water.

Hyperbilirubinemia is Multisystem problem MU-8 . Hemolytic disease of the newborn owns DAT, Rh, ABO, IVIG, and exchange as hemolysis tools in chapter 7. This section owns the pigment: production, conjugation, screening, phototherapy physics, neurologic risk, and conjugated versus unconjugated branching. ExamFinch independent study material covers the patient problem as listed on the current Neonatal CCRN Test Plan. It is not a substitute for plotting the infant on the actual AAP 2022 figure hanging in your nursery.

Physiology you can teach in one minute

Senescent red cells release heme. Heme oxygenase and biliverdin reductase produce unconjugated (indirect) bilirubin , which is fat-soluble and neurotoxic if unbound. Albumin carries it to the liver. Hepatocytes conjugate it via UGT1A1 to water-soluble conjugated (direct) bilirubin, which goes into bile and stool. In the gut, beta-glucuronidase can deconjugate pigment, and it is reabsorbed ( enterohepatic circulation ). Anything that increases production (hemolysis, polycythemia, swallowed blood, cephalohematoma), decreases conjugation (prematurity, Gilbert/Crigler-Najjar spectrum, hypothyroidism, hypoxia), displaces albumin binding (acidosis, some drugs), or increases recirculation (delayed stooling, exclusive breastfeeding with poor intake, bowel obstruction) raises the unconjugated pool.

Physiologic jaundice is common after 24 hours in a well infant with a modest rise and a good course. Pathologic clues: jaundice in the first 24 hours , rapidly rising TSB, hemolysis, a sibling who needed exchange, family G6PD, prematurity, sepsis, or a conjugated fraction that is not “a little direct.” Breastfeeding jaundice (inadequate intake, dehydration, delayed stool) is different from breast-milk jaundice (a later, prolonged unconjugated rise in a thriving infant). Neither label is a reason to ignore a high TSB.

TcB and TSB

Transcutaneous bilirubin (TcB) is a screening estimate. It is useful for well-baby pathways and for deciding who needs a serum level. It is less reliable at higher values, after phototherapy has begun (bleached skin fools the meter), and in some skin-pigment and device combinations. Total serum bilirubin (TSB) is the treatment number. When you are near a threshold, when phototherapy is on, when hemolysis is in play, or when the infant is preterm or ill, draw TSB. Direct (conjugated) fraction matters when cholestasis is possible; a “total only” stick does not answer a 3-week-old with pale stools.

Plot the value against age in hours , not “day of life 2.” A TSB of 14 mg/dL at 18 hours is a different emergency from 14 mg/dL at 96 hours.

AAP 2022 principles—without a fake AACN nomogram

The American Academy of Pediatrics 2022 clinical practice guideline revision for infants 35 or more weeks of gestation replaced the 2004 hour-specific approach with new phototherapy and escalation-of-care / exchange graphs. Broadly, many phototherapy thresholds are higher than 2004, which is a safety and overtreatment conversation in nurseries, not a reason to withhold treatment from a rising hemolytic infant. Thresholds are lower when neurotoxicity risk factors are present. Commonly listed factors include isoimmune hemolytic disease, G6PD deficiency, asphyxia, lethargy, temperature instability, sepsis, acidosis, and albumin below about 3.0 g/dL. Gestational age itself is built into the graphs (a 35-week infant is not plotted as if term).

Escalation of care in AAP 2022 language is the zone approaching exchange, often discussed as about 2 mg/dL below the exchange threshold, where intensive phototherapy, hydration, and preparation for exchange happen now . Exchange transfusion remains the intervention when TSB is at or above the exchange graph despite intensive phototherapy, or when acute bilirubin encephalopathy is present even if the number has not “caught up.”

Infants under 35 weeks are not the 2022 term/late-preterm figure. Units use separate expert guidance and local curves. Do not import a 40-week number onto a 28-week infant.

What you must not do on this exam: invent a table of fake milligram-per-deciliter cutoffs and label it AACN official. The Neonatal CCRN Test Plan names hyperbilirubinemia as a patient problem. It does not reprint AAP figures. Independent ExamFinch teaching describes AAP 2022 principles (hour of life, gestation, risk factors, intensive phototherapy, exchange for dangerous unconjugated levels or encephalopathy). Your unit protocol is the bedside law.

DAT and hemolysis

The direct antiglobulin test (DAT, direct Coombs) detects antibody or complement on the infant’s red cells. A positive DAT supports isoimmune hemolytic disease (ABO, Rh, or other minor antibodies). Pair it with blood types, a reticulocyte count, a hemoglobin/hematocrit, a smear, and the rate of TSB rise. Chapter 7 taught Rh versus ABO patterns and IVIG as an adjunct to reduce hemolysis. This section’s job is: positive DAT plus a fast-rising unconjugated bilirubin is not “physiologic,” phototherapy must be intensive , and exchange plus IVIG enter the conversation sooner.

A negative DAT does not exclude hemolysis. G6PD, hereditary spherocytosis, and other intrinsic red-cell disorders can destroy cells without antibody on the membrane. Ethnicity, family history, a high reticulocyte count, and a bilirubin that outruns phototherapy still count.

Conjugated versus unconjugated

Feature Unconjugated (indirect) Conjugated (direct)

Chemistry Fat-soluble, albumin-bound, neurotoxic unbound fraction Water-soluble, already processed by the liver

Typical drivers Hemolysis, prematurity, Gilbert/Crigler-Najjar, breastfeeding/intake, bruising Biliary obstruction, infection (including UTI), TPN-associated cholestasis, metabolic disease, hypothyroidism, alpha-1 antitrypsin, inspissated bile after severe hemolysis

Stool/urine Normal pigment early Acholic stools , dark urine

Phototherapy Mainstay for dangerous unconjugated TSB Does not open a blocked bile duct; bronze-baby risk if you blast a high direct fraction

Exchange For dangerous unconjugated levels / encephalopathy Not a kernicterus treatment for isolated conjugated pigment

Next step Plot hour-specific TSB; DAT; feed; intensive lights Cholestasis workup, including biliary atresia timing (chapter 8)

Definitions of a “high” direct fraction vary (for example, a direct bilirubin above about 1.0–2.0 mg/dL or more than about 20% of total, depending on the lab and the guideline you are using). AACN does not pick the percentage. The clinical rule is: a predominantly conjugated picture is not physiologic jaundice of the second day of life.

Kernicterus and acute bilirubin encephalopathy

Bilirubin-induced neurologic dysfunction (BIND) is the spectrum. Acute bilirubin encephalopathy can begin with lethargy, hypotonia, and a poor suck, then progress to hypertonia, retrocollis , opisthotonos , a high-pitched cry, fever, and seizures. That progression is an exchange conversation, not a “increase lights in the morning” conversation. Chronic kernicterus is permanent injury: choreoathetoid cerebral palsy, upward-gaze palsy, sensorineural hearing loss / auditory neuropathy, and dental enamel dysplasia. Prematurity, hemolysis, hypoalbuminemia, and acidosis lower the threshold at which unbound bilirubin crosses a vulnerable blood-brain barrier. Prevention is timely TSB, intensive phototherapy, IVIG when isoimmune hemolysis is driving the rise, and exchange when indicated—not withholding milk to “let the jaundice declare.”

Intensive versus fiberoptic phototherapy, eyes, and milk

Phototherapy converts unconjugated bilirubin in the skin to lumirubin and other isomers that can be excreted without conjugation. Efficacy depends on wavelength (blue-green, often discussed around 460–490 nm ), irradiance , surface area , and distance from the source.

Intensive phototherapy means high spectral irradiance—commonly taught as at least 30 μW/cm²/nm in the relevant band—using LED banks or equivalent, maximizing exposed skin (diaper as small as safety allows), and often a second source (overhead plus undersource). Measure irradiance with a meter; do not assume a decorative blue glow is intensive.

Fiberoptic blankets and pads deliver lower irradiance to a smaller area. They are useful as adjuncts , during transport, or for mild elevations in well infants. They are not a substitute for intensive overhead (plus extra surface) therapy when TSB is near escalation. Combining a high-intensity bank with a fiberoptic pad can be part of an intensive setup; the blanket alone usually is not.

Eye protection is mandatory while overhead lights are on. Check that shields have not slipped and that they are not occluding the nares. Remove shields periodically for bonding and eye checks per protocol. Monitor temperature: lights can overheat, and undressing can cool an ELBW infant (section 13.2). Phototherapy increases IWL; do not treat that with bottles of free water . Feed milk (or IV dextrose-containing fluids if the infant cannot feed) to maintain hydration and stooling, which interrupts enterohepatic recirculation. Extra water does not conjugate bilirubin and can cause hyponatremia (section 13.1).

Turn the infant, watch for bronze-baby syndrome if conjugated bilirubin is high, and expect a rebound TSB after lights stop—especially with hemolysis. Re-plot. Follow hearing screening in infants who had severe hyperbilirubinemia.

Worked scenario: a 36-week infant at 20 hours of life is jaundiced, DAT-positive, TSB already near the AAP 2022 phototherapy line for a 36-week infant with isoimmune risk. This is intensive phototherapy, hydration with milk, a hematocrit and reticulocyte count, IVIG discussion, and a plotted trajectory—not a fiberoptic wrap in a bassinet and a TcB in the morning.

Exam traps: treating TcB as the treatment number after lights start; quoting a fake AACN nomogram; phototherapy as treatment of biliary atresia; missing G6PD because the DAT is negative; calling a fiberoptic pad “intensive”; skipping eye shields; giving free water; and waiting out opisthotonos. Practice: /practice/ccrn-neonatal .

Loading diagram... Bilirubin Pathway, Screening, and Branch Points